Form 4: Atara Biotherapeutics CEO Sells Shares for Tax Obligations

Atara Biotherapeutics' President and CEO, AnhCo Nguyen, sold 2,996 shares of common stock on March 2, 2026, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• AnhCo Nguyen, President and CEO, and Director of Atara Biotherapeutics, Inc. (ATRA), reported transactions on March 2, 2026.
• The transactions involved the automatic sale of common stock to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units.
• A total of 2,996 shares of common stock were disposed of across four separate transactions.
• The sale prices per share ranged from $5.079 to $5.087.
• Following these transactions, AnhCo Nguyen beneficially owns 61,978 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was an automatic, non-discretionary transaction to cover tax liabilities associated with RSU vesting, rather than a strategic divestment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that 'sale-to-cover' transactions, where executives sell shares to satisfy tax obligations upon the vesting of equity awards, are a common and routine occurrence in the biotechnology and broader corporate sectors. These transactions are generally not indicative of a change in management's outlook on the company's prospects or a discretionary divestment.

Stakeholder Impact

• Shareholders: The transaction represents a minor, non-discretionary reduction in insider ownership, which is a routine part of executive compensation and is unlikely to have a significant impact on shareholder sentiment or the company's operational strategy.

Key Dates

Recommendation

The sale of shares by the President and CEO was an automatic transaction to cover tax obligations related to restricted stock unit vesting, which is a routine event and does not reflect a discretionary decision to sell. Therefore, it does not provide new information to alter an investment thesis, suggesting a 'hold' recommendation.

Keywords

Atara Biotherapeutics, ATRA, AnhCo Nguyen, Form 4, Insider Transaction, Stock Sale, CEO, Restricted Stock Units, Tax Withholding